Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor

[Reuters] – * Gilead plans to sell Sovaldi in India for $300 a month (Adds detail, background) Approximately 150 million people in the world live with chronic hepatitis C infection, most of them . . . → Read More: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor Similar Articles: Stock Update (NASDAQ:GILD): UK cost body backs pricey Gilead hepatitis pill for some patients Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – England agrees funding for Gilead hepatitis C drug Company Update (NASDAQ:GILD): Texas Medicaid holds off on proposed limits for Gilead hepatitis drug
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.